Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bellus Health Inc
(NQ:
BLU
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bellus Health Inc
< Previous
1
2
Next >
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
June 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
May 12, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Inc. (NASDAQ: BLU) Leading the Way in Tuesday Trading Based on Percentage Gain
April 18, 2023
Via
Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
May 03, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BELLUS Health Announces Meeting Updates
April 26, 2023
From
BELLUS Health Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
April 18, 2023
From
BELLUS Health Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation
April 05, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
March 21, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
February 08, 2023
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
November 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
October 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
September 06, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
August 22, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
August 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
July 18, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
July 13, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
July 13, 2022
From
BELLUS Health Inc.
Via
Business Wire
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
July 12, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in the William Blair Biotech Focus Conference
July 05, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
May 11, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
May 02, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
April 25, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
February 23, 2022
From
BELLUS Health Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.